{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:22:32Z","timestamp":1793866952036,"version":"4.6.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"\n Importance<\/jats:title>\n Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP). However, its effectiveness and safety have yet to be confirmed in a large-scale study.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy and safety of dupilumab in patients with BP and evaluate factors that potentially affect short-term and long-term outcomes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort study was conducted from January 1, 2021, to July 31, 2022. The median (IQR) follow-up period was 24.6 (11.5-38.4) weeks. This multicenter study was performed in 6 dermatology departments of the National Autoimmune Bullous Diseases Cooperative Group of China. Adult patients with BP that received 300 mg of dupilumab every 2 weeks following an initial dose of 600 mg were included. Patients were eligible if they had a clinical presentation of BP combined with immunological or pathological evidence. Patients with drug-induced BP, with less than 4 weeks of follow-up, and who received dupilumab or any other biologics within 6 months were excluded.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the proportion of patients who achieved disease control within 4 weeks. Disease control was defined as the absence of new lesions and pruritus, combined with the healing of existing lesions. Complete remission rates, relapse rates, changes in Bullous Pemphigoid Disease Area Index (BPDAI) scores, itching numerical rating scale (NRS) scores, laboratory results within 64 weeks, and adverse events (AEs) were also assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 146 patients (median [IQR] age, 73 [64-85] years; 86 [58.9%] male patients) included in the study, 127 (87.0%) patients achieved disease control within 4 weeks, with a median (IQR) time of 14 (7-14) days. A total of 52 (35.6%) patients achieved complete remission, and 13 (8.9%) patients relapsed during the observation period. The complete remission rate and cumulative relapse rate at week 64 were 62.5% (5 of 8) and 30.9%, respectively. There was rapid and sustained improvement in clinical indicators and laboratory examination results after dupilumab treatment, including BPDAI scores, itching NRS scores, serum anti-BP180 and anti-BP230 antibodies, total IgE levels, and eosinophil count. Of these 146 patients, 107 (73.3%) did not report any AEs. The most common AEs were infections and eosinophilia. Serum anti-BP180 antibody levels of greater than 50 relative units (RU)\/mL (OR, 3.63; 95% CI, 0.97-12.61;\n P<\/jats:italic>\n \u2009=\u2009.045) were associated with 4-week disease control, and male patients were more likely to relapse (HR, 10.97; 95% CI, 1.42-84.92;\n P<\/jats:italic>\n \u2009=\u2009.02).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective cohort study, dupilumab treatment was associated with improved clinical symptoms in patients with BP. The safety profile was favorable, although concurrent infection and eosinophilia might pose potential concerns. This study suggests that patients with anti-BP180 antibody levels of at least 50 RU\/mL and female sex may respond better.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2428","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:02:11Z","timestamp":1690974131000},"page":"953","source":"Crossref","is-referenced-by-count":102,"title":["Evaluation of Dupilumab in Patients With Bullous Pemphigoid"],"prefix":"10.1001","volume":"159","author":[{"given":"Liuqi","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Liang","sequence":"additional","affiliation":[{"name":"Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Feng","sequence":"additional","affiliation":[{"name":"Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing, China"},{"name":"National Autoimmune Bullous Disease Cooperative Group, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9863","key":"doi230031r1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"doi230031r2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients.","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi230031r3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature.","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"doi230031r4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review.","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"doi230031r5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi230031r6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia.","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230031r7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease: role of eosinophils in the production and release of these chemokines.","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol"},{"key":"doi230031r8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2021.09.014","article-title":"Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab.","volume":"17","author":"Bal","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"7","key":"doi230031r9","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1111\/jdv.v36.7","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids: a monocentric real-life study.","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi230031r10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v35.9","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab.","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol Ther"},{"key":"doi230031r11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid.","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"doi230031r12","doi-asserted-by":"crossref","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus.","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"issue":"4","key":"doi230031r13","doi-asserted-by":"publisher","DOI":"10.5070\/D3274053155","article-title":"Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol Online J"},{"key":"doi230031r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2020.100031","article-title":"Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid.","volume":"2","author":"Mihailescu","year":"2020","journal-title":"Curr Probl Cancer Case Rep"},{"issue":"9","key":"doi230031r15","doi-asserted-by":"publisher","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"10","key":"doi230031r16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid.","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi230031r17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series.","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi230031r18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ajd.v62.4","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: a case letter.","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas J Dermatol"},{"key":"doi230031r19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid.","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"doi230031r20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v35.8","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"issue":"10","key":"doi230031r21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.v36.10","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"doi230031r22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"doi230031r23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230031r24","first-page":"11","article-title":"Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases (2022).","volume":"55","author":"Chinese Society of Dermatology, China Dermatologist Association","year":"2022","journal-title":"Zhonghua Pifuke Zazhi"},{"issue":"6","key":"doi230031r26","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/bjd.v184.6","article-title":"International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230031r27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi230031r28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"10079","key":"doi230031r29","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"doi230031r30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2022.04.029","article-title":"Bullous pemphigoid: three main clusters defining 3 outcome profiles.","volume":"87","author":"Guerrois","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi230031r31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00403-018-1817-9","article-title":"BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"doi230031r32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1046\/j.1365-2133.1997.6581643.x","article-title":"Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients.","volume":"136","author":"Bernard","year":"1997","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi230031r33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1067\/mjd.2000.103986","article-title":"IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.","volume":"42","author":"D\u00f6pp","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi230031r34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.","volume":"88","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"1","key":"doi230031r35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2020.03.017","article-title":"Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid.","volume":"83","author":"Geller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230031r36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis.","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"doi230031r25","unstructured":"Chinese Collaborative Network for Autoimmune Bullous Diseases. Consensus of diagnosis and treatment of autoimmune bullous disease. Paper presented at: The fifth session of the National Autoimmune Bullous Diseases Cooperative Group; 2021; Beijing, China."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2808114\/jamadermatology_zhao_2023_oi_230031_1695075698.39036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T11:14:58Z","timestamp":1695208498000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2808114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}